A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models
Laboratory studyOther animalsWith quercetin
This study tested palmitoylethanolamide together with quercetin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Male laboratory rats, in two models: paw swelling caused by carrageenan and joint damage caused by sodium monoiodoacetate
- Dose used in the study
- 10 or 20 mg/kg of a co-ultramicronised palmitoylethanolamide and quercetin product by mouth, compared with the anti-inflammatory drug meloxicam
- Duration
- A single dose in the swelling model. Three doses a week for 21 days in the joint model.
- What was measured
- Paw swelling, sensitivity to heat and touch, movement, cartilage damage under the microscope and markers of inflammation
What the authors reported
The combination reduced paw swelling by 30 to 45% in the first model, along with lower myeloperoxidase activity, a marker of inflammatory cell infiltration. In the joint model it improved pain thresholds and movement to a degree comparable with meloxicam, protected cartilage and lowered tumour necrosis factor alpha, interleukin 1 beta, metalloproteases 1, 3 and 9, and nerve growth factor.
Limits of this study
A laboratory study in rats with chemically induced injury. The authors state that whether the findings carry over to dogs and cats was still under investigation, and that they did not test palmitoylethanolamide alone. The competing interests statement says one author, Cuzzocrea, is a co-inventor on patents with Epitech Group, and no other author declared a competing interest. Funding was not visible on the page checked.
Source
PubMed 28768536 · doi:10.1186/s12917-017-1151-z
Entry checked against the full text at the publisher (Springer) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.